BioAtla Investor Presentation Deck

Phase 2, part 1 BA3011 NSCLC initial interim analysis supports advancing preparations for part 2 potentially registrational study in PD-1 failure NSCLC ORR (%) bicatla 50 45 40 35 30 25 20 15 10 5 0 25% 5/20 NSQ+SQ Interim data- Data cut-off of Jan 4, 2023 Average prior lines of therapy = 3 NSQ - non-squamous; SQ - squamous 28% 5/18 All NSQ 40% 4*/10 NSQ monotherapy PD-1 or EGFR failure 44% 4*/9 NSQ monotherapy PD-1 failure only Responses include 4 partial responses (*) and one complete response (**) 13% 1**/8 NSQ BA3011 + nivolumab 0/2 SQ BioAtla| Overview 19

View entire presentation